• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Updates Guidance for Trials During COVID-19 with Three New Topics

FDA Updates Guidance for Trials During COVID-19 with Three New Topics

May 18, 2020

The FDA last week updated its March guidance on managing clinical trials during COVID-19 by saying that sites can conduct patient visits via video conference with some advance planning.

When using video conferencing for patient visits, the guidance recommends putting in place procedures to maintain patients’ privacy, developing an identity verification method so the investigator and patient can confirm their respective identities, and making sure the staff conducting the visit are trained on the use of real-time telemedicine tools.

“Sponsors will likely be relieved that FDA considers real-time video interactions, including telemedicine, as a live exchange of information,” instead of electronic records that would be subject to the agency’s Part 11 regulation, says WCG Clinical Vice President of IRB Compliance David Borasky.

Clinical trials being conducted as a postmarketing requirement may experience delays in reporting to the FDA, the guidance says, and sponsors should inform the agency as soon as possible of any COVID-19-related issues that could cause them to miss interim, completion and/or final report deadlines. Sponsors should provide an explanation of COVID-19’s impact on the timeline and propose a revised schedule for reports.

The guidance also says that if trial participants can’t access the trial site for assessments, it’s permissible to use alternative laboratory or imaging centers if such tests are routinely performed in those settings. However, if the assessments are the basis for formal hypothesis testing, the sponsor should consult with the FDA review division first.

To read the guidance, click here: https://bit.ly/361s91e.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing